Special Issue

LCMV – A Pillar for Immunology Research

Message from the Guest Editor

Since its original description by Charles Armstrong in 1934, lymphocytic choriomeningitis virus (LCMV) has been a useful instrument in the immunologists' toolbox. LCMV has been central to the discovery of a wide range of immunological concepts, both relevant to the antiviral host response and beyond. They include groundbreaking experiments by Rolf Zinkernagel and Peter Doherty that led to the discovery of MHC molecules and ultimately the concept of self tolerance, and Michael Oldstone's work on viral immunopathology and chronic infection. Likewise, the seminal works of Rafi Ahmed, E. John Wherry and many others to characterise functional T cell exhaustion laid the foundation for the development of new treatments for chronic infections and malignant diseases. There is no doubt that the study of LCMV will continue to open new avenues of research in immunology. The goal of this Special Issue is to assemble both reviews and original research manuscripts that focus on LCMV as both a model and pathogen to illuminate the diverse nature of anti-viral responses.

Guest Editor

Dr. Markus J. Hofer

School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia

Deadline for manuscript submissions

closed (30 June 2019)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed



mdpi.com/si/14214

Viruses

MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.8 CiteScore 7.3 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).